论文部分内容阅读
Objective:To observe the clinical effects of kanglaite(KLT)capsules combined with transcatheter arterial chemo-embolization(TACE)in treating patients with mid or late-stage primary hepatocellular carcinoma(HCC).Methods:Sixty-five cases were randomly divided into 2 groups,32 patients in combination group received the treatment of KLT capsules + TACE and 33 patients in control group were treated with TACE alone.The objective response rate(RR),serum alpha fetoprotein(AFP),peripheral blood T lymphocyte subgroups(T-LS),quality of life(QOL),time to progression(TTP)and adverse reaction were observed and compared between 2 groups.Results:The objective response rate and serum alpha fetoprotein levels had no significant difference between the two groups(P > 0.05).Combination group was superior to control group in quality of life(QOL),time to progression(TTP),peripheral blood T lymphocyte subgroups(CD3+,CD4+,CD4+CD8 ratio)and liver adverse reactions,with significant differences(P < 0.05).Conclusion:KLT capsules combined with TACE is an effective method to treat primary hepatocellular carcinoma(HCC)patients who have lost the opportunity of surgical therapy.
Objective: To observe the clinical effects of kanglaite (KLT) capsules combined with transcatheter arterial chemo-embolization (TACE) in treating patients with mid or late-stage primary hepatocellular carcinoma (HCC). Methods: Sixty-five cases were randomly divided into 2 groups, 32 patients in combination group received the treatment of KLT capsules + TACE and 33 patients in control group were treated with TACE alone. The objective response rate (RR), serum alpha fetoprotein (AFP), peripheral blood T lymphocyte subgroups (T- LS), quality of life (QOL), time to progression (TTP) and adverse reaction were observed and compared between 2 groups. Results: The objective response rate and serum alpha fetoprotein levels had no significant difference between the two groups (P> 0.05 ) .Combination group was superior to control group in quality of life (QOL), time to progression (TTP), peripheral blood T lymphocyte subgroups (CD3 +, CD4 +, CD4 + CD8 ratio) and liver adverse reactions, with significant differences (P <0.05) .Conclu sion: KLT capsules combined with TACE is an effective method to treat primary hepatocellular carcinoma (HCC) patients who have lost the opportunity of surgical therapy.